Hudson Bay Capital Management’s NeuroSense Therapeutics NRSN Stock Holding History

Hudson Bay Capital Management’s Portfolio NRSN Stock Details NRSN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-75,000	Closed	-$184K	–	1275
2021 Q4	$184K	Buy	+75,000	New	+$228K	﹤0.01%	909

Other funds holding NRSN

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

FIA

FNY Investment Advisers New York $278M AUM 98.99% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Hudson Bay Capital Management's NRSN Position: Q1 2022 in Review

Hudson Bay Capital Management sold out of NeuroSense Therapeutics (NRSN) in Q1 2022, closing a stake of 75,000 shares — an estimated $184K sold.

Hudson Bay Capital Management first reported a position in NRSN in Q4 2021 and held it in 1 quarter. The position peaked at $184K in Q4 2021. 9 funds tracked by Wall St. Rank hold NRSN as of Q1 2022.

Hudson Bay Capital Management reported no remaining NeuroSense Therapeutics position as of Q1 2022 after selling out during the quarter.
Hudson Bay Capital Management sold 75,000 NeuroSense Therapeutics shares in Q1 2022, an estimated $184K.
Hudson Bay Capital Management first reported a position in NeuroSense Therapeutics in Q4 2021 and held it in 1 quarter.
Hudson Bay Capital Management's NeuroSense Therapeutics position peaked at $184K in Q4 2021.
9 funds tracked by Wall St. Rank held NeuroSense Therapeutics as of Q1 2022.

Based on Hudson Bay Capital Management's 13F filing for Q1 2022, filed 16 May 2022.